To foster therapeutic development in oncology, XenTech performs preclinical pharmacology studies using one of the world's largest and best characterized collection of patient-derived tumor xenograft models (PDX) established without intermediary cell culture.
29 november – 2 december 2016 | Munich, Germany | EORTC-NCI-AACR
This year in Munich is the 28th @EORTC-NCI-AACR Symposium This event brings together around 2000 academics, scientists and pharmaceutical industry representatives from across the globe to discuss innovations in anti cancer drug development, target selection and new discoveries in molecular biology. We will be glad to meet you there. Come and see us at Booth […]
Contract Research Organization
XenTech is primarily a contract research organization (CRO) specializing in preclinical evaluation of novel anti-tumor agents. The company also conducts internal R&D programs....